The CXL USA study group was formed in 2009 to serve as a resource for helping patients find multicenter clinical trials of corneal collagen crosslinking in the US and international experts for those outside the US.
Corneal collagen cross-linking (CXL) is a technique that was first used in 1998 to treat patients with a disease called keratoconus.
In keratoconus, the cornea (the front clear window of the eye) can become weak, thin, and irregularly shaped. Instead of keeping its normal round shape, corneas with keratoconus can bulge forward into the shape of a cone causing poor vision.
CXL is now being performed for patients with this condition in approximately 450 centers throughout the world. Through a research study, our practice is now able to provide this investigational treatment to our patients using advanced technology for cross-linking.
Corneal Collagen Cross-Linking Study Group
Transepithelial (epithelium-on) corneal cross-linking is an investigational procedure in the US, and the medical device associated with this procedure is limited by Federal law to investigational use.